Get the Stockscreener App
116.50
3.04%
3.44
After Hours:
114.00
-2.50
-2.15%
Icon Plc stock is traded at $116.50, with a volume of 1.36M.
It is up +3.04% in the last 24 hours and up +18.48% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$113.06
Open:
$113.31
24h Volume:
1.36M
Relative Volume:
0.79
Market Cap:
$8.90B
Revenue:
$8.10B
Net Income/Loss:
$599.48M
P/E Ratio:
15.75
EPS:
7.3969
Net Cash Flow:
$971.54M
1W Performance:
+9.35%
1M Performance:
+18.48%
6M Performance:
-37.98%
1Y Performance:
-19.75%
1-Day Range:
$112.53
$116.65
1-Week Range:
$102.53
$116.65
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
116.50 | 8.63B | 8.10B | 599.48M | 971.54M | 7.3969 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Is It Too Late to Buy Icon PLC (ICLR) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
Icon Plc (NASDAQ:ICLR) Short Interest Update - MarketBeat
Barclays Maintains Icon PLC(ICLR.US) With Hold Rating, Maintains Target Price $120 - Moomoo
Timber Creek Capital Management LLC Makes New $5.65 Million Investment in Icon Plc $ICLR - MarketBeat
Is ICON (NasdaqGS:ICLR) Offering An Opportunity After Recent Share Price Volatility? - Sahm
ICON plc stock (IE0005711209): Is clinical trial demand strong enough to drive U.S. investor upside? - AD HOC NEWS
Massachusetts Financial Services Co. MA Has $429.50 Million Holdings in Icon Plc $ICLR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neogen (NEOG) - The Globe and Mail
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $180 - 富途牛牛
Trinity Street Asset Management LLP Increases Stock Position in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR) Stock Forecasts - Yahoo! Finance Canada
ICON Public Limited Company (ICLR) stock price, news, quote and history - Yahoo Finance UK
Icon Plc $ICLR Shares Acquired by Aberdeen Group plc - MarketBeat
Icon: Downgrading Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback - Morningstar
Downgrading Icon's Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback - Morningstar
How ICON’s AI-Focused Partnership with Advarra Could Reshape ICLR’s Clinical Trial Efficiency Narrative - simplywall.st
Healthcare Rpo Market Is Going to Boom | • ICON plc • Syneos Health • Labcorp - openPR.com
ICLR Technical Analysis & Stock Price Forecast - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
Fund Update: 1,985,017 ICON PLC (ICLR) Shares Added to GREENHAVEN ASSOCIATES INC Portfolio - Moomoo
Fund Update: 1,985,017 ICON PLC (ICLR) shares added to GREENHAVEN ASSOCIATES INC portfolio - Quiver Quantitative
Walter Public Investments Inc.'s Icon PLC(ICLR) Holding History - GuruFocus
ICON PLC earnings missed by $0.02, revenue was in line with estimates - Investing.com South Africa
Icon (ICLR) Dividend-Payout-to-FFO - GuruFocus
ICLR 3-Year EBITDA Growth Rate: 28.40% — 176% Above Median - GuruFocus
MEX:ICLR EV-to-OCF: 9.32 — 56% Below Median - GuruFocus
Icon PLC Forges Strategic Alliance Amidst Financial Review - AD HOC NEWS
Icon Plc $ICLR Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Icon PLC (ICLR) Stock Price Up 3.93% on Mar 30 - GuruFocus
Precision Trading with Icon Plc (ICLR) Risk Zones - Stock Traders Daily
ICON Stock Trades At Deep Discount Amid Probe - Let's Data Science
Is ICON Public Limited Company (ICLR) A Good Stock To Buy Now? - Insider Monkey
Icon Plc (NASDAQ:ICLR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Why ICON (ICLR) Is Up 5.1% After New AI-Powered Clinical Trial Partnership With Advarra - simplywall.st
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Clinical research provider Icon stock crashes on accounting probe - MSN
ICON (ICLR) Upgraded by BMO Capital Markets Amid Valuation Appea - GuruFocus
Icon plc buy BMO Capital Markets - sharewise.com
ICON PLC : BMO Raises to Outperform From Mark - Moomoo
BMO Capital Upgrades Icon PLC(ICLR.US) to Buy Rating, Cuts Target Price to $130 - 富途牛牛
BMO upgrades ICON stock rating on pharma backdrop improvement - Investing.com UK
Strategic Partnership Aims to Boost Icon's Efficiency Amid Accounting Scrutiny - AD HOC NEWS
WGI DM, LLC's Icon PLC(ICLR) Holding History - GuruFocus
Icon, Advarra enter partnership, introduces ‘research-ready’ site network model - TipRanks
ICON, Advarra Partner on Connected Site Network Model - Contract Pharma
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model (1) - PharmiWeb.com
Rep. Julia Letlow Sells Icon Plc (NASDAQ:ICLR) Stock - MarketBeat
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model - Business Wire
JPMorgan Chase & Co. Sells 614,165 Shares of Icon Plc $ICLR - MarketBeat
ICON set to report delayed earnings after accounting scandal - Investing.com UK
ICON set to report delayed earnings after accounting scandal By Investing.com - Investing.com UK
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):